High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

Cumberland Pharmaceuticals saw its shares pop almost 34 percent on heavy volume Tuesday following positive results from a ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Pharmaceuticals announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.53 and traded as ...

NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...

Cumberland Pharmaceuticals stock opened at $2.43 on Tuesday. The business’s fifty day moving average is $1.93 and its two-hundred day moving average is $1.54. The company has a debt-to-equity ...

Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.